Conference Roundup

Brolucizumab effective treatment for DME visual impairment

The 52-week results from 2 phase 3 studies show that brolucizumab (Beovu; Novartis) provides robust vision improvements and superior anatomical outcomes with dosing every 12-week (q12w) intervals in more than 50% of patients with diabetic macular edema (DME), according to a presentation at ARVO 2021 Virtual. KITE and KESTREL are...